Do you have to promote your OptimizeRx inventory?

Roth Capital Markets analyst Richard Baldry says OptimizeRx (OptimizeRx Company Inventory Quote, Chart, Information, Analysts, Financials NASDAQ:OPRX) reported outcomes largely in keeping with expectations on income however delivered a robust profitability beat attributable to price controls.

In a March 6 gross sales evaluation, Baldry maintained a “Purchase” ranking on OptimizeRx whereas reducing his 12-month worth goal to $18.00 following the corporate’s fourth-quarter outcomes.

OptimizeRx reported This fall 2025 income of $32.2-million, roughly in keeping with Baldry’s $31.8-million estimate and flat year-over-year. Nonetheless, Adjusted EBITDA reached a document $12.0-million, almost double Baldry’s $6.5-million forecast and 35% above the prior quarterly document set in This fall 2024.

Professional forma earnings per share additionally considerably exceeded expectations at $0.45, almost double Baldry’s $0.24 estimate.

Baldry stated the income slowdown displays headwinds affecting pharmaceutical business advertising budgets following a coverage initiative launched by the Donald Trump administration that seeks to tie U.S. drug costs to the bottom costs provided globally.

As pharmaceutical firms navigate negotiations associated to the “most favoured nation” pricing framework, Baldry stated many have curtailed discretionary advertising spending and shortened contract durations, creating near-term strain for OptimizeRx.

“This leaves OPRX’s means to affect revenues severely curtailed near-term,” Baldry stated.

The corporate expects these headwinds to persist by way of the primary half of 2026. Baldry now forecasts first-quarter income declining about 12.5% year-over-year and second-quarter income falling roughly 10%.

In consequence, he lowered his 2026 income forecast to $114.0-million from $123.8-million beforehand, in keeping with the higher finish of administration’s revised steering vary of $109-million to $114-million.

Regardless of the weaker income outlook, Baldry elevated his earnings expectations following the sturdy margin efficiency.

“With well-controlled prices seemingly sustainable… we view OPRX’s greater core earnings engine as more likely to persist,” he stated.

Baldry now forecasts 2026 Adjusted EBITDA of $24.8-million and professional forma EPS of $1.01, up from prior estimates of $22.0-million and $0.90, respectively.

Whereas near-term income progress might stay risky, Baldry stated OptimizeRx’s profitability enhancements and not too long ago approved $10-million share buyback ought to assist help the inventory in the course of the present interval of uncertainty.

-30-